Prothena to Participate in Upcoming September Investor Conferences
Globe Newswire - Tue Aug 30, 3:05PM CDT
DUBLIN, Ireland, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ
PRTA: 49.98 (-0.54)
Prothena (PRTA) Reports Wider-than-Anticipated Loss in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:45AM CDT
Prothena (PRTA) reported a wider-than-expected loss of $1.18 per share in the second quarter of 2016.
ZTS: 51.10 (+0.35), ANIP: 59.74 (-1.12), PRTA: 49.98 (-0.54)
Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update
Globe Newswire - Tue Aug 02, 3:05PM CDT
- Net cash used in operating and investing activities was $32.3 million in the second quarter and $57.7 million for the first six months of 2016; strong quarter-end cash and restricted cash position of $447.0 million supports advancement of multiple clinical development programs
PRTA: 49.98 (-0.54)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 74.54 (-0.51), BIIB: 305.63 (-2.23), ABT: 42.02 (-0.81), JNJ: 119.34 (-0.13), GILD: 78.38 (+0.46), MRK: 62.79 (+0.08), PFE: 34.80 (-0.08), SGNT: 21.76 (+0.03), ABBV: 64.10 (-0.06), PRTA: 49.98 (-0.54), NVS: 78.77 (-0.57)
What's in Store for Prothena (PRTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:44PM CDT
Prothena Corporation plc (PRTA) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 24.19 (-0.23), IRWD: 13.34 (-0.08), PRTA: 49.98 (-0.54), EXEL: 11.15 (+0.11)
Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
Globe Newswire - Thu Jun 09, 3:05PM CDT
- All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers
PRTA: 49.98 (-0.54)
Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
Globe Newswire - Mon May 23, 3:05PM CDT
- New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosis
PRTA: 49.98 (-0.54)
Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
Globe Newswire - Thu May 19, 3:05PM CDT
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
PRTA: 49.98 (-0.54)
Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016
Globe Newswire - Mon May 09, 3:05PM CDT
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
PRTA: 49.98 (-0.54)
Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 187.18 (-3.04), PRTA: 49.98 (-0.54), NKTR: 17.85 (+0.34)
Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update
Globe Newswire - Tue May 03, 3:05PM CDT
- Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programs
PRTA: 49.98 (-0.54)
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 4.62 (-0.06), BIIB: 305.63 (-2.23), ABT: 42.02 (-0.81), JNJ: 119.34 (-0.13), AERI: 19.36 (-0.06), AEGR: 1.63 (+0.01), PRTA: 49.98 (-0.54)
Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 51.10 (+0.35), AGIO: 36.84 (+0.22), PRTA: 49.98 (-0.54)